Navigation Links
Magnetic resonance imaging before ablation for atrial fibrosis helps predict success of treatment
Date:9/1/2013

AMSTERDAM, The Netherlands In patients with atrial fibrillation, delayed enhancement magnetic resonance imaging (DE-MRI) performed before ablative treatment can stage the degree of damaged heart tissue (atrial fibrosis) and help predict whether treatment will be successful or not, according to results of Delayed Enhancement - MRI determinant of successful Catheter Ablation of Atrial Fibrillation (DECAAF) trial.

"The DECAAF results show that stage of atrial fibrosis prior to ablation is a new, powerful, independent predictor of outcome," said lead investigator Nasir Marrouche, MD, from the CARMA Center at the University of Utah in Salt Lake City, USA.

"By performing this imaging before ablative treatment we can triage patients according to likelihood of treatment success, and avoid ablative procedures in those patients for whom it is unlikely to work. If a patient has late stage 3 or stage 4 fibrosis their chance of being cured is only 30-35% which is really low, but if they're in an early stage their chance of cure is 60-80%," he said.

The DECAAF trial included 260 atrial fibrillation (AF) patients with atrial fibrosis who were undergoing ablation.

The patients, from 15 centers in USA, Europe and Australia were a mean age of 59 years, and 64.6% of them had paroxysmal AF.

High resolution Delayed Enhancement MRI (DE‐MRI) was performed up to 30 days before ablation in all patients to determine the presence and extent of atrial fibrosis, while post- ablation DE-MRI was performed at 90-days follow-up in 177 of the subjects, to determine the extent of residual ablation.

At the 90-day follow-up, recurrence of arrhythmia was noted in 88 of the 260 patients (33.8%) based on Holter monitors and electrocardiograms.

Multivariate analysis revealed two independent predictors of successful ablation or recurrent symptoms were stage of atrial fibrosis before ablation (P<0.001) as well as residual fibrosis after (P<0.001).

Specifically, patients whose pre-ablation fibrosis was stage 1 (defined as less than 10% damaged atrial tissue) had an 85.8% success rate, those with stage 2 (10% - 20% damage) had a 63.3% success rate, those with stage 3 (20% - 30% damage) had a 55% success rate and those with stage 4 (more than 30% damage) had a 31% success rate.

For every increased percentage of fibrosis before ablation, there was 6.3% increased risk of recurrent symptoms after ablation (hazard ratio [HR] 1.063), said Dr. Marrouche.

Similarly, for every percentage of residual fibrosis there was an 8.2% increased risk of recurrent symptoms (HR 1.082).

A secondary finding of the study, based on post-ablation imaging, showed that the type of ablation clinicians used also had an impact on success rates. The choice of procedure was not dictated in the study protocol and was left to the discretion of individual treating physicians.

After comparing pre-ablation images of fibrotic tissue, with post-ablation images showing the extent of residual fibrosis, a surprise finding was that pulmonary vein ablation, which is the standard-of-care in atrial fibrillation ablation candidates, is not the best ablative approach, said Dr. Marrouche.

"We do ablation around the pulmonary veins because we have assumed for years that the trigger for AF comes from the vein that's the standard of care," he said. "But what we found in DECAAF is that ablation of the veins did not predict outcome. In fact, the most important predictor of outcome, along with stage of atrial fibrosis, was the degree of ablation of the fibrotic tissue. Rather than targeting the pulmonary veins, procedures which ablated fibrotic tissue produced better outcomes - the more that was targeted, the better the outcome."


'/>"/>

Contact: ESC Press Office
press@escardio.org
44-773-005-7146
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. New research confirms efficacy of transcranial magnetic stimulation for depression
2. In-utero exposure to magnetic fields associated with increased risk of obesity in childhood
3. Is magnetic therapy effective for tinnitus?
4. Into the magnetic resonance scanner with a cuddly toy
5. Klingg, the Wearable Magnetic Earphone Cord Holder is Released by Mokao Design
6. Magnetic Implant May Ease Chronic Acid Reflux
7. Data Devices International Announces the Introduction of the DataGauss Hard Disk Drive and Magnetic Media Degausser
8. New Magnetic Bracelet with Gemstones Announces Superior Magnetics
9. Magnetic Brain Stimulation May Temporarily Dull Nicotine Craving
10. New Sergio Lub Magnetic Bracelet Announced Superior Magnetics
11. Superior Magnetics Announced it Has a Magnetic Bracelet for Bursitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... Bionic Sports Nutrition LLC, an American company devoted to developing ... successful January ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition ... provide its products to all clients at reasonable prices. At the ECRM trade show, ...
(Date:1/20/2017)... boca raton florida (PRWEB) , ... January 20, 2017 , ... ... trial at the Dana Farber Cancer Institute. For Betsy, the clinical trial has ... and her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian ...
(Date:1/20/2017)... ... ... “The Angel”: a heartwarming and earnest tale of faith and believing ... “The Angel” is the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, ... , When asked of her new book, Marjorie says, “‘The Angel’ was written as ...
(Date:1/20/2017)... ... 20, 2017 , ... “Christmas in Suffolk”: a story of love, secrets, ... lives in Lafayette, Indiana where she works in a daycare and looks for inspiration ... Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure of love ...
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... Mass. , Jan. 20, 2017 /PRNewswire/ ... Keystone Symposia Conference, "PI3K Pathways in Immunology, ... Inc. (NASDAQ: INFI ) ... immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase-gamma ... able to help overcome resistance to checkpoint ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
(Date:1/20/2017)... 2017 Stock-Callers.com today evaluates the following ... ), Novo Nordisk A/S (NYSE: NVO ), Sucampo ... Holdings Inc. (NASDAQ: PTX ). These stocks belong ... th , 2017, finishing near its session lows. As per ... 0.7%, while shares of health care companies in the S&P ...
Breaking Medicine Technology: